ArticleBiomedical chromatography : BMC2026
Characterization of Liposomal and Free Aqueous Extracts of Ceratonia siliqua: Evaluation of Phenolic Contents and Antimicrobial, Antimutagenic, Enzyme Inhibitory, and Antiproliferative Activities.
Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceratonia siliqua (carob) is a Mediterranean medicinal plant rich in phenolic contents but limited by poor bioavailability. To address this, an aqueous carob extract was formulated into liposomes and characterized. Phenolic profiles of the free (CBE) and the liposomal extracts (LCBE) were compared by the HPLC. Genotoxic safety and biological activities of both extracts were evaluated. HPLC analysis identified key phenolic acids in both formulations; while the concentration of gallic acid was determined as 23.5 ppm in CBE and 18.5 ppm in LCBE, caffeic acid levels were determined as 43.5 ppm in CBE and 24.5 ppm in LCBE. In addition, protocatechuic acid followed a similar trend, with concentrations of 55.1 ppm in CBE and 35.1 ppm in LCBE. Biologically, the LCBE showed enhanced antibacterial activity, particularly against Escherichia coli. The LCBE demonstrated stronger competitive inhibition of AChE and α-amylase when compared with the free extract, suggesting potential relevance for enzyme-modulating and glycemic support. In preliminary MTT-based cell viability screening, LCBE showed relatively greater activity than CBE in MCF-7 cells; however, this effect was weak, while PC-3 and MDA-MB-231 cells showed limited responsiveness under the tested conditions. Further selectivity and mechanistic studies should be done in vivo bioavailability/pharmacokinetics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.